PT  - JOURNAL ARTICLE
AU  - Julia Matas
AU  - Brendan Kohrn
AU  - Jeanne Fredrickson
AU  - Kelly Carter
AU  - Ming Yu
AU  - Ting Wang
AU  - Xianyong Gui
AU  - Thierry Soussi
AU  - Victor Moreno
AU  - William M. Grady
AU  - Miguel A. Peinado
AU  - Rosa Ana Risques
TI  - Colorectal cancer is associated with the presence of cancer driver mutations in normal colon
AID  - 10.1101/2021.10.11.21264780
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.11.21264780
4099  - http://medrxiv.org/content/early/2021/10/14/2021.10.11.21264780.short
4100  - http://medrxiv.org/content/early/2021/10/14/2021.10.11.21264780.full
AB  - While somatic mutations in colorectal cancer (CRC) are well characterized, little is known about the accumulation of cancer mutations in the normal colon prior to cancer. Here we have developed and applied an ultra-sensitive, single-molecule mutational test based on CRISPR-DS technology, which enables mutation detection at extremely low frequency (<0.001) in normal colon from patients with and without CRC. We found oncogenic KRAS mutations in the normal colon of about one third of patients with CRC but in none of the patients without CRC. Patients with CRC also carried more TP53 mutations than patients without cancer, and these mutations were more pathogenic and formed larger clones, especially in patients with early onset CRC. Most mutations in normal colon were different from the driver mutations in tumors suggesting that the occurrence of independent clones with pathogenic KRAS and TP53 mutations is a common event in the colon of individuals that develop CRC.SIGNIFICANCE Our results suggest a prevalent process of somatic mutation and evolution in the normal colon of patients with CRC, which can be detected by ultra-sensitive sequencing of driver genes and potentially employed clinically for CRC risk prediction.Competing Interest StatementRAR is a consultant and equity holder at TwinStrand Biosciences Inc. and an equity holder at NanoString Technologies Inc. RAR is named inventor on patents owned by the University of Washington and licensed to TwinStrand Biosciences Inc. MAP is cofounder and equity holder at Aniling. MAP laboratory has received research funding from Celgene. VM is equity holder of Aniling.Funding StatementThis work was supported in part by i-PFIs (IFI16/00012) and M-AES (MV19/00042) research fellowships from Instituto de Salud Carlos III to JM; Agencia Estatal de Investigacion (RTI2018-094009-B-100) to MAP; startup funds from the Department of Laboratory Medicine and Pathology to RAR; R50CA233042 to MY; P01CA077852, P30CA042014, P30CA15704, R01189184, R01CA194663, R01CA207371, R01CA220004, U01CA206110, U54CA143862, Listwin Family Foundation, Cottrell Family Fund, R.A.C.E. Charities, Seattle Translational Tumor Research, Rodger C. Haggitt Endowed Chair, and W.H. Geiger Family Foundation to WMG; and Agency for Management of University and Research Grants (AGAUR) of the Catalan Government grant 2017SGR723 to VM.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted following protocols approved by Institutional Review Board committees at the University of Washington and the Fred Hutchinson Cancer Research Center.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors